VERV – verve therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $32.00. They now have a "buy" rating on the stock.
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an "outperform" rating on the stock.
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at HC Wainwright from $15.00 to $14.00. They now have a "buy" rating on the stock.
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
Form SC 13G Verve Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Form SC 13G/A Verve Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Form SC 13G/A Verve Therapeutics, Inc. Filed by: BlackRock, Inc.
Form 10-Q Verve Therapeutics, Inc. For: Sep 30
Form 8-K Verve Therapeutics, Inc. For: Nov 05
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.